Medical Health & Life Science Research News

Research report explores the global exocrine pancreatic insufficiency pipeline therapeutics review

Exocrine Pancreatic Insufficiency Pipeline Review H1 2017 pharmaceutical guide provides Exocrine Pancreatic Insufficiency therapeutics development by companies with there all amjor and minor project and drug profiles.Report helps to Formulate corrective measures for pipeline projects by understanding Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Agency -.

Exocrine Pancreatic Insufficiency Pipeline Review H1 2017 provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape. Pharmaceutical and Healthcare latest Exocrine Pancreatic Insufficiency - Pipeline Review H1 2017 provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion.

- Agency -.

 PDF Report at: www.reportsnreports.com/contacts/.aspx?name=1057937 .

Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Exocrine Pancreatic Insufficiency and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 1 respectively.

Exocrine Pancreatic Insufficiency - Companies Involved in Therapeutics Development Discussed: Anthera Pharmaceuticals Inc, Celleron Therapeutics Ltd, Cilian AG, Laboratoires Mayoly Spindler SAS, Nordmark Arzneimittel GmbH & Co KG.

Exocrine Pancreatic Insufficiency Drug Profiles Discussed: burlulipase, Cilase, CXD-101, liprotamase, MS-1819.

Report at: http://www.reportsnreports.co m/contacts/.aspx?name=1057937

The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Featured News & Press Releases Covered

  1. May 15, 2017: Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
  2. Apr 11, 2017: AzurRx Provides Update on MS1819 Phase II Trial
  3. Dec 21, 2016: AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency.
  4. Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
  5. Jun 28, 2016: Anthera Provides Clinical Program Update for Sollpura
  6. Mar 19, 2015: Anthera Announces $3 Million Research Award from Cystic Fibrosis Foundation Therapeutics for Development of Sollpura - a Novel Enzyme Therapy
  7. Nov 20, 2014: Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
  8. Aug 01, 2012: Cilian Receives €1m Grant For Development Of Cilase
  9. Apr 15, 2011: Lilly Receives Complete Response Letter From FDA For Liprotamase For Treatment Of Exocrine Pancreatic Insufficiency
  10. Jan 12, 2011: Lilly Announces FDA Panel Recommendation For Liprotamase
  11. Jun 22, 2010: Protea Biosciences And Mayoly-­Spindler Announce Human Clinical Trial For New Biopharmaceutical.

Scope:

  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Exocrine Pancreatic Insufficiency (Gastrointestinal).
  2. The pipeline guide reviews pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  5. The pipeline guide reviews key companies involved in Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  6. The pipeline guide evaluates Exocrine Pancreatic Insufficiency (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  8. The pipeline guide reviews latest news related to pipeline therapeutics for Exocrine Pancreatic Insufficiency (Gastrointestinal).

Access Exocrine Pancreatic Insufficiency Pipeline Review H1 2017 Complete Report at www.reportsnreports.com/.aspx?name=1057937 .

List of Tables:

  1. Number of Products under Development for Exocrine Pancreatic Insufficiency, H1 2017
  2. Number of Products under Development by Companies, H1 2017
  3. Products under Development by Companies, H1 2017
  4. Number of Products by Stage and Target, H1 2017
  5. Number of Products by Stage and Mechanism of Action, H1 2017
  6. Number of Products by Stage and Route of Administration, H1 2017
  7. Number of Products by Stage and Molecule Type, H1 2017
  8. Exocrine Pancreatic Insufficiency - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
  9. Exocrine Pancreatic Insufficiency - Pipeline by Celleron Therapeutics Ltd, H1 2017
  10. Exocrine Pancreatic Insufficiency - Pipeline by Cilian AG, H1 2017
  11. Exocrine Pancreatic Insufficiency - Pipeline by Laboratoires Mayoly Spindler SAS, H1 2017
  12. Exocrine Pancreatic Insufficiency - Pipeline by Nordmark Arzneimittel GmbH & Co KG, H1 2017
  13. Exocrine Pancreatic Insufficiency - Dormant Projects, H1 2017
  14. Exocrine Pancreatic Insufficiency - Discontinued Products, H1 2017.

 

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.